Jazz Pharmaceuticals (JAZZ) PT Rises To $147 At Mizuho After Two Recent Catalysts

Mizuho Securities analyst, Irina Koffler, reiterated her Neutral rating on shares of Jazz Pharmaceuticals (NASDAQ: JAZZ) and raised the price target to $147 from $137 after the recent approval of Sunosi (solriamfetol for excessive sleepiness), and positive data (last night) in the Phase III trial of JZP-258 (low sodium Xyrem). Despite the positive impact of the events, the analyst believes they were widely expected.

The analyst stated "We believe that Jazz trades at a slight discount to its peers because of persistent concerns around Xyrem competition, commercial execution of new launches, and uncertainty about
the future of Erwinaze. Therefore, we don't expect a meaningful inflection to the stock from the JZP-258 (low sodium Xyrem) results announced after the close".

For an analyst ratings summary and ratings history on Jazz Pharmaceuticals click here. For more ratings news on Jazz Pharmaceuticals click here.

Shares of Jazz Pharmaceuticals closed at $136.54 yesterday.

You May Also Be Interested In

• Advance Auto Parts (AAP) PT Lowered to $48 at DA Davidson Following 25% Selloff Post Q2 Results
• Deere (DE) PT Lowered to $728 at UBS as Agricultural Machinery Cycle Gets Closer
• Cummins (CMI) PT Lowered to $675 at Jefferies